Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents— post hoc analyses of the ASCEND-ND and ASCEND-D trials
Nephrology Dialysis Transplantation · 2023
DOI: 10.1093/ndt/gfac342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2023. Verfasst von Ajay K Singh und 17 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Hematinics, Erythropoietin, Neoplasms, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, GlaxoSmithKline, NIDDK.
Abstract (Originalsprache)
Background
The prespecified on-treatment analysis of ASCEND-ND (NCT02876835) raised concerns about a higher relative risk of cancer-related adverse events (AEs) with daprodustat vs darbepoetin in patients with anaemia of CKD. This concern was not observed in dialysis patients in ASCEND-D (NCT02879305).
Methods
ASCEND-ND randomized 3872 patients to daprodustat or darbepoetin. ASCEND-D randomized 2964 patients to daprodustat or conventional erythropoiesis-stimulating agents (ESAs). In both studies ESA comparators used different dosing intervals (3/week, 1/week, every 2 or every 4 weeks). The prespecified on-treatment approach examined relative risks for cancer AEs up to the last dose date + 1 day. In these analyses, owing to different dosing intervals between arms, Cox models were used to estimate the daprodustat effect by various follow-up periods (censoring at last dose date, last dose date + dosing intervals, or end of study).
Results
In ASCEND-ND, the safety of daprodustat vs darbepoetin on cancer-related AEs depended on the duration of follow-up after last dose date: hazard ratio (HR) 1.04 [95% confidence interval (CI) 0.77, 1.40] at end of study [HR 1.12 (95% CI 0.81, 1.56) for last dose date + dosing interval; HR 1.50 (95% CI 1.04, 2.15) for last dose date + 1 day]. In ASCEND-D, no excess risk of cancer-related AEs was observed with any model examined.
Conclusions
Prespecified on-treatment analyses for cancer-related AEs appeared to result in biased risk estimates in ASCEND-ND by preferentially under-counting events from patients assigned to darbepoetin. Analyses accounting for longer darbepoetin dosing intervals, or extending follow-up, resulted in attenuation of effect estimates towards neutrality, similar to ASCEND-D, where ESA comparator dosing intervals are closer to daprodustat.
Trial registration
The ASCEND-ND trial is registered with ClinicalTrials.gov (NCT02876835); the ASCEND-D trial is registered with ClinicalTrials.gov (NCT02879305).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
- University Hospital of Würzburg, Würzburg, Germany.
- Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland.
- Georgetown-Lombardi Comprehensive Cancer Center, Washington DC, USA.
ORCID-Profile: Finnian R McCausland, Christoph Wanner, Janet Wittes
Förderung
- NIDDK NIH HHS
- GlaxoSmithKline
- NIDDK
Zitieren
APA
Singh, A. K., McCausland, F. R., Claggett, B. L., Wanner, C., Wiecek, A., Atkins, M. B., Carroll, K., Perkovic, V., McMurray, J. J. V., Wittes, J., Snapinn, S., Blackorby, A., Meadowcroft, A., Barker, T., DiMino, T., Mallett, S., Cobitz, A. R., & Solomon, S. D. (2023). Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents— post hoc analyses of the ASCEND-ND and ASCEND-D trials. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfac342
Vancouver
Singh AK, McCausland FR, Claggett BL, Wanner C, Wiecek A, Atkins MB, et al. Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents— post hoc analyses of the ASCEND-ND and ASCEND-D trials. Nephrology Dialysis Transplantation. 2023. doi:10.1093/ndt/gfac342
BibTeX
@article{Singh2023,
author = {Singh, Ajay K and McCausland, Finnian R and Claggett, Brian L and Wanner, Christoph and Wiecek, Andrzej and Atkins, Michael B and Carroll, Kevin and Perkovic, Vlado and McMurray, John J V and Wittes, Janet and Snapinn, Steven and Blackorby, Allison and Meadowcroft, Amy and Barker, Tara and DiMino, Tara and Mallett, Stephen and Cobitz, Alexander R and Solomon, Scott D},
title = {Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents— post hoc analyses of the ASCEND-ND and ASCEND-D trials},
journal = {Nephrology Dialysis Transplantation},
year = {2023},
doi = {10.1093/ndt/gfac342}
}
EUVIMED